Idexx Laboratories generated $4.4B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $1.1B with a 24.63% net margin. Gross margin stands at 62.05% and operating margin at 31.63%. Diluted EPS is $13.59, which grew 0.3% year-over-year. Based on the Q1 2026 filing.